Who is sponsoring NCT05385549?

NCT05385549 is sponsored by Asan Medical Center.

What drugs are being tested in NCT05385549?

Interventions in NCT05385549: Imatinib Mesylate.

What condition does NCT05385549 study?

NCT05385549 studies Gastrointestinal Stromal Tumors.

Is NCT05385549 still recruiting?

NCT05385549 is currently recruiting now. Last updated 8 August 2025.

Last reviewed 2025-08-08 · How we verify

NCT05385549

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk

Recruiting now Phase 2 Last updated 8 August 2025

What this trial tests

Phase 2 trial testing Imatinib Mesylate in Gastrointestinal Stromal Tumors in 35 participants. Currently enrolling.

Timeline

7 September 2022

Primary endpoint
30 April 2030

30 April 2030

Quick facts

Lead sponsor	Asan Medical Center
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	7 September 2022
Primary completion	30 April 2030
Estimated completion	30 April 2030
Sites	1 location across South Korea

Drugs / interventions tested

Imatinib Mesylate — full drug profile →

Conditions studied

Gastrointestinal Stromal Tumors — all drugs for Gastrointestinal Stromal Tumors →

Sponsor

Asan Medical Center

Who can join

20 and older, any sex, with Gastrointestinal Stromal Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, the investigators aim to investigate the efficacy and safety of 5 years of adjuvant imatinib treatment in patients with tumor rupture defined by Nishida classification or those with a tumor size 10cm or larger and a mitotic index of 10/50HPFs or higher.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeting the Unmet Need in Gastrointestinal Stromal Tumors: A Contemporary Review of Investigational Clinical Trials and Therapeutic Landscape.
Belančić A, Prejac J, Golčić M, Adžić G, et al · · 2026 · PMID 42075805 · DOI 10.3390/ph19040548

Verify or expand the search:

Other trials of Imatinib Mesylate

Trials testing the same drug.

NCT05970900 — Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST · Phase 3 · not yet recruiting
NCT05623774 — A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg · Phase 1 · completed
NCT04953052 — A Randomized Study to Investigate the Effect of Intravenous Imatinib on the Amount of Oxygen in the Lungs and Blood of A · Phase 2 · withdrawn
NCT04416750 — Positioning Imatinib for Pulmonary Arterial Hypertension · Phase 2 · unknown
NCT04006769 — Entacapone Combination With Imatinib for Treatment of GIST · EARLY_PHASE1 · completed

Other recruiting trials for Gastrointestinal Stromal Tumors

Currently open trials in the same condition.

NCT06805825 — A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres · Phase 1 · recruiting
NCT06326346 — GIST Oral Paclitaxel(Liporaxel) · Phase 2 · recruiting
NCT06087263 — Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation · Phase 2 · active not recruiting
NCT05366816 — ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST · Phase 2 · recruiting
NCT05905887 — Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor · Phase 2 · recruiting

Other Asan Medical Center trials

Trials by the same sponsor.

NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05385549 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
Last refreshed: 8 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05385549.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing